36.6 F
New York
Wednesday, January 27, 2021

AstraZeneca [NYSE: AZN] And Sanofi’s [NASDAQ: SNY] Nirsevimab Shows Positive Result In Phase 2 Trial

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

AstraZeneca PLC [NYSE: AZN] and development partner Sanofi’s [NASDAQ: SNY] nirsevimab has shown a promising result in Phase 2 clinical trial, companies disclosed today. Both Sanofi and AstraZeneca have signed an agreement in March 2017 for the development and commercialization of Nirsevimab.

The current Phase 2 study result has shown a significant reduction in Respiratory Syncytial Virus (RSV) infections which required medical care in the healthy premature infant. Nirsevimab has decreased the infections by 70% and the need for medical care by 78%.

Respiratory Syncytial Virus (RSV) is a lower respiratory tract infection. RSV is a contagious virus that infects the respiratory tract and the most common cause of pneumonia and bronchiolitis. Nirsevimab which is co-developed by Sanofi and AstraZeneca reduced the infections caused by RSV in infants who are experiencing their first RSV season.

Shares of AstraZeneca traded up 0.57% during the trading of Wednesday. Its closing price is $56.64. AZN has a 52-weeks low and high range of $36.15-$64.94, respectively. AZN has a day high range of $57.05 and a day low range of $56.09.

It had a trading volume of roughly 5.04 million as compared to the average volume of 7.14 million. Continuing to look at its profitability, its return on assets (ROA) is 2.50%, return on equity (ROE) is 12.30%, and return on investment (ROI) is 8.30%.

AZN has a Gross Margin of 79.60%, a Profit Margin of 6.00%, and an Operating Margin of 12.10%. Turning our focus on liquidity, its quick ratio is 0.60 and the current ratio is 0.80.

On the other hand, Sanofi’s shares have exhibited a change of 1.95% at $52.84 during the trading session on Wednesday. Its return on investment (ROI) is 3.50%. SNY has a Gross Margin of 68.00%, a Profit Margin of 13.60%, and an Operating Margin of 16.20%.

In the past 52-weeks of trading, its stocks fluctuated between the low of $37.62 and a high of $55.00. SNY has moved up 40.46% from 52-weeks of low range and moved down -3.93% from the 52-weeks of high range.

Phase 2b trial of Nirsevimab fulfilled the primary and secondary endpoints. Nirsevimab gained a statistically significant 70.1% (95% CI: 52.3%-81.2%) reduction of medically attended RSV LRTI contrasted to placebo through 150 days post-dose on the primary endpoint.

On the secondary endpoint, nirsevimab achieved a 78.4% (95% CI: 51.9%-90.3%) relative reduction in the need for medical care due to RSV LRTI compared to placebo through 150 days post-dose.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...